AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 215.59B +35.2% |
| Revenue (ttm) | 43.64B +8.6% |
| Net Income | 7.60B +45.3% |
| EPS | 4.86 +45.3% |
| Shares Out | 1.55B |
| PE Ratio | 28.61 |
| Forward PE | 18.26 |
| Dividend | 2.36 (1.69%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 434,311 |
| Average Volume | 1,577,485 |
| Open | 13,816 |
| Previous Close | 13,900 |
| Day's Range | 13,582 - 13,910 |
| 52-Week Range | 9,651 - 15,732 |
| Beta | 0.28 |
| RSI | 31.84 |
| Earnings Date | Apr 29, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsNews
AstraZeneca to make $405 million investment in Britain, PM Starmer says
Prime Minister Keir Starmer said on Wednesday that Britain's biggest company AstraZeneca would invest 300 million pounds ($405 million) in the country, after pausing large-scale projects last y...
AstraZeneca Gets Revenue Boost From Cancer Drugs
AstraZeneca reported rises in revenue and core earnings for the first quarter, saying growing sales of its cancer and rare-disease drugs lifted results.
AstraZeneca beats profit expectations, keeps annual outlook unchanged
AstraZeneca beat first-quarter sales and profit expectations and maintained its 2026 outlook on Wednesday, as demand for its cancer drugs and investments in the U.S. and China helped the dr...
Guardant Health (GH) Faces Minimal Impact from AstraZeneca Advisory Meeting
Guardant Health (GH) Faces Minimal Impact from AstraZeneca Advisory Meeting
Amgen (AMGN) and AstraZeneca (AZN) Launch Real-Time Clinical Trials with FDA
Amgen (AMGN) and AstraZeneca (AZN) Launch Real-Time Clinical Trials with FDA
Pre-Market Earnings Report for April 29, 2026 : ABBV, AZN, TTE, APH, UBS, GD, ADP, REGN, CNI, PSX, ETR, GRMN
The following companies are expected to report earnings prior to market open on 04/29/2026. Visit our Earnings Calendar for a full list of expected earnings releases.AbbVie Inc. (ABBV)is reporting for...
AstraZeneca (AZN) to Test AI-Driven Data Reporting in Clinical Trials
AstraZeneca (AZN) to Test AI-Driven Data Reporting in Clinical Trials
Earnings To Watch: AstraZeneca PLC (LSE:AZN) Reports Q1 2026 Result
Earnings To Watch: AstraZeneca PLC (LSE:AZN) Reports Q1 2026 Result
AstraZeneca (AZN) Receives US Approval for Breztri Aerosphere in Asthma Treatment
AstraZeneca (AZN) Receives US Approval for Breztri Aerosphere in Asthma Treatment
AstraZeneca (AZN) Gains FDA Approval for Asthma Treatment
AstraZeneca (AZN) Gains FDA Approval for Asthma Treatment
AstraZeneca (AZN) Receives FDA Approval for Breztri Aerosphere in Asthma Treatment
AstraZeneca (AZN) Receives FDA Approval for Breztri Aerosphere in Asthma Treatment
AstraZeneca (AZN) Gains FDA Approval for Saphnelo Self-Administration
AstraZeneca (AZN) Gains FDA Approval for Saphnelo Self-Administration
SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's SAPHNELO® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen, for the treatment of ...
AstraZeneca: FDA Approves Saphnelo For Subcutaneous Self-administration
(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said its Saphnelo has been approved in the US for self-administration as a once-weekly autoinjector, the Saphnelo Pen, for the treatment of adult p...
Insights Into Astrazeneca (AZN) Q1: Wall Street Projections for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Astrazeneca (AZN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...
T Rowe Price Equity Income Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage
T Rowe Price Equity Income Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage
AstraZeneca (AZN) Seeks Accelerated Approval for Ultomiris in IgAN Treatment
AstraZeneca (AZN) Seeks Accelerated Approval for Ultomiris in IgAN Treatment
Germany risks missing out on new drugs, AstraZeneca CEO tells paper
AstraZeneca's CEO told daily Handelsblatt on Tuesday that Germany risks missing out on new drugs that the Anglo-Swedish drugmaker plans to launch if the nation sticks with plans to keep spending on ...
AstraZeneca I CAN Phase III Interim Analysis Meets Primary Goal
LONDON (dpa-AFX) - AstraZeneca PLC (AZN) on Tuesday said an interim analysis of its Phase III I CAN study showed that Ultomiris met the primary endpoint in adults with immunoglobulin A nephropathy...
AstraZeneca's Ultomiris reduces urine protein in late-stage trial of rare kidney disease
AstraZeneca said on Tuesday its rare blood disorder drug Ultomiris met the main goal of a late stage trial, showing a reduction in protein found in the urine of patients with a rare ki...
AstraZeneca (AZN) Achieves Success in Late-Stage COPD Trial for Tozorakimab
AstraZeneca (AZN) Achieves Success in Late-Stage COPD Trial for Tozorakimab
Tozorakimab (AZN) Shows Promise in COPD Treatment in Phase III Trial
Tozorakimab (AZN) Shows Promise in COPD Treatment in Phase III Trial
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinica...
AstraZeneca Says Tozorakimab Meets Main Goal In Phase III COPD Trial
LONDON (dpa-AFX) - AstraZeneca PLC (AZN) on Monday said its pivotal Phase III MIRANDA trial of tozorakimab in patients with Chronic Obstructive Pulmonary Disease met its primary endpoint, demonstr...
AstraZeneca's tozorakimab delivers sharp reduction in COPD flare‑ups
AstraZeneca said on Monday its experimental treatment tozorakimab met the main goal in a late-stage trial, reflecting a sharp reduction in moderate-to-severe flare-ups of chronic obstruc...